Search results for: Maria Lowe
Filter search results
Latest estimates show that 20 people a day die in unrelieved pain across the UK at the end of their lives
26 November 2024
…of their life, even if the highest levels of hospice-level care are available to patients, using conservative assumptions that provide the lowest possible estimate. This is a 15% increase between…
OHE submission to the UK Parliamentary Inquiry on an Ageing Society
20 May 2025
…age-based differences in the number of days reported as absenteeism and presenteeism for the respondents in our sample (in absolute terms, numbers were actually lower across the board for individuals aged…
Bold politics – what about the economics?: An overview of President Trump’s ‘Most Favoured Nation’ Executive Order
2 June 2025
…of global pharmaceutical prices with American patients paying lower prices. Pegging US drug prices to other countries’ is not a new idea This EO marks a significant departure from a previous…
Abolishing Pharmaceutical Rebates in the US? Looking at the Trade-Offs
12 March 2019
…the discussion at that meeting. Rebates are a key negotiating tool for payers and help produce a lower ‘net’ price for drugs that can help reduce the overall costs of…
Value, Access, and Incentives for Innovation: Policy Perspectives on Alternative Models for Pharmaceutical Rebates
1 March 2019
…to be answered. Rebates are a key negotiating tool for payers and help produce a lower “net” price for drugs that can help reduce the overall costs of drug spending….
OHE Annual Lecture: Universal Health Coverage: the Holy Grail?
8 June 2014, 11:00pm
…The health systems of most other high income countries similarly embody the ideal of universal health coverage. Yet low- and lower-middle-income countries have recently been on the receiving end of…
Part 2: 2010 Lecture on US Health Reform
27 July 2010
…most likely to purchase individual policies. Finally, the new financial penalties for many individuals who do not purchase insurance will be lower – often dramatically so – than the cost…
Antibacterials: Roundtable Addresses the Critical Issues
10 November 2011
…The current situation is due primarily to two causes: inappropriate use in humans and animals, and the decline in the development of new antibacterials, largely because of lower returns on…
New Seminar Briefing: Is Pharmaceutical R&D Experiencing a Productivity Crisis?
14 June 2012
…since 2000 and have remained at a level lower than during the 1990s. He identifies two reasons for this. First, development times (patent filing to market launch) have increased markedly. …